LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations
Phase of Trial: Phase II
Latest Information Update: 19 Jun 2019
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Pharmacodynamics; Pharmacogenomic
- 07 Nov 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 01 Mar 2018 Planned End Date changed from 1 Apr 2018 to 1 Nov 2018.